Market research
0AL.F Agile Therapeutics, Inc
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 13M
- P/E ratio
- Not available
- Analyst target
- 3.83
- Dividend yield
- 0.0%
- Beta
- 1.14
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- Not available
- Market cap
- 13M
- P/E ratio
- Not available
- Analyst target
- 3.83
- Dividend yield
- 0.0%
- Beta
- 1.14
About
About Agile Therapeutics, Inc
Agile Therapeutics, Inc., a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was incorporated in 1997 and is headquartered in Princeton, New Jersey.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the 0AL.F discussion.
5 years, 5 months ago
Agile Therapeutics, Inc is currently in a long term downtrend where the price is trading 46.5% below its 200 day moving average.
From a valuation standpoint, the stock is 82.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 231.9.
Agile Therapeutics, Inc's total revenue rose by inf% to $749K since the same quarter in the previous year.
Its net income has dropped by 192.6% to $-18M since the same quarter in the previous year.
Finally, its free cash flow fell by 421.2% to $-17M since the same quarter in the previous year.
Based on the above factors, Agile Therapeutics, Inc gets an overall score of 2/5.